Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Operating Margin (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Operating Margin for 14 consecutive years, with 14.07% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 1637.0% to 14.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.58% through Dec 2025, up 1248.0% year-over-year, with the annual reading at 12.58% for FY2025, 1248.0% up from the prior year.
  • Operating Margin hit 14.07% in Q4 2025 for Ani Pharmaceuticals, down from 15.91% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 27.19% in Q1 2021 to a low of 38.94% in Q4 2021.
  • Historically, Operating Margin has averaged 0.55% across 5 years, with a median of 4.43% in 2024.
  • Biggest five-year swings in Operating Margin: surged 4294bps in 2021 and later plummeted -5696bps in 2022.
  • Year by year, Operating Margin stood at 38.94% in 2021, then soared by 105bps to 1.93% in 2022, then skyrocketed by 165bps to 5.11% in 2023, then tumbled by -145bps to 2.3% in 2024, then surged by 713bps to 14.07% in 2025.
  • Business Quant data shows Operating Margin for ANIP at 14.07% in Q4 2025, 15.91% in Q3 2025, and 6.57% in Q2 2025.